의료진프로필

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

Shen, JN; Choi, YL; Lee, T; Kim, H; Chae, YK; Dulken, B; Bogdan, S; Huang, M; Fisher, GA; Park, S; Lee, SH; Hwang, JE; Chung, JH; Kim, L; Song, H; Pereira, S; Shin, S; Lim, Y; Ahn, CH; Kim, S; Oum, C; Kim, S; Park, G; Song, S; Jung, W; Kim, S; Bang, YJ; Mok, TSK; Ali, SM; Ock, CY

First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data

Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ

VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

Hochmair, MJ; Vermaelen, K; Mountzios, G; Carcereny, E; Dooms, C; Lee, SH; Morocz, EM; Kato, T; Ciuleanu, TE; Dy, G; Parente, MBMCS; O'Byrne, KJ; Chu, QSC; De Castro, G Jr; Girard, N; Snyder, W; Tran, Q; Kormany, W; Houk, B; Curioni-Fontecedro, A

PD-L1 expression in resected lung adenocarcinoma: prevalence and prognostic significance in relation to the IASLC grading system

Hwang, S; Hong, TH; Kim, HK; Cho, J; Lee, G; Choi, S; Park, S; Lee, SH; Lee, Y; Jeon, YJ; Lee, J; Park, SY; Cho, JH; Choi, YS; Kim, J; Zo, JI; Shim, YM; Choi, YL

Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B

Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ

Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)

Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH

Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer

Kim, K; Kim, H; Shin, I; Noh, SJ; Kim, JY; Suh, KJ; Kim, YN; Lee, JY; Cho, DY; Kim, SH; Kim, JH; Lee, SH; Choi, JK

Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes

Song, S; Koh, Y; Kim, S; Lee, SM; Kim, HU; Ko, JM; Lee, SH; Yoon, SS; Park, S

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study

Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA

Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection

Kim, SY; Jeong, S; Lee, WK; Jeon, Y; Kim, YJ; Park, S; Lee, DG; Go, D; Song, SH; Lee, SH; Woo, HG; Yoon, JK; Park, YS; Kim, YT; Lee, SH; Kim, KH; Lim, Y; Kim, JS; Kim, HP; Bang, D; Kim, TY

Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer

Naqash, AR; Mccallen, JD; Mi, E; Iivanainen, S; Marie, MA; Gramenitskaya, D; Clark, J; Koivunen, JP; Macherla, S; Jonnalagadda, S; Polsani, S; Jiwani, RA; Hafiz, M; Muzaffar, M; Brunetti, L; Stroud, CRG; Walker, PR; Wang, K; Chung, YM; Ruppin, E; Lee, SH; Yang, L; Pinato, DJ; Lee, JS; Cortellini, A

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

Ang, YLE; Zhao, XT; Reungwetwattana, T; Cho, BC; Liao, BC; Yeung, R; Loong, HH; Kim, DW; Yang, JCH; Lim, SM; Ahn, MJ; Lee, SH; Suwatanapongched, T; Kongchauy, K; Ou, QX; Yu, RY; Tai, BC; Goh, BC; Mok, TSK; Soo, RA

Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma

Koh, Y; Kim, H; Joo, SY; Song, SL; Choi, YH; Kim, HR; Moon, B; Byun, J; Hong, JS; Shin, DY; Park, S; Lee, KH; Lee, KT; Lee, JK; Park, D; Lee, SH; Jang, JY; Lee, H; Kim, JA; Yoon, SS; Park, JK

Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients

Lee, H; Seo, S; Won, S; Park, WY; Choi, JY; Lee, KH; Lee, SH; Moon, SH

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Kim, H; Park, S; Jung, HA; Lee, SH; Park, K; Ahn, YC; Oh, D; Ahn, MJ

Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement

Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer

Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K

Comment on Leveraging NGS Data to Refine Immunotherapy Response Prediction in NSCLC: PD-L1 Copy Number, Tumor Mutation Burden, and Beyond

Hong, TH; Bang, YH; Joe, C; Choi, YL; Lee, SH

Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer

Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer

Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

Choi, SW; Jung, HA; Cho, HJ; Kim, TM; Park, CK; Nam, D; Lee, SH

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

Wakelee, H; Liberman, M; Kato, T; Tsuboi, M; Lee, SH; Gao, SG; Chen, KN; Dooms, C; Majem, M; Eigendorff, E; Martinengo, GL; Bylicki, O; Rodriguez-Abreu, D; Chaft, JE; Novello, S; Yang, J; Keller, SM; Samkari, A; Spicer, JD

Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC

Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

Wakelee, HA; Liberman, M; Kato, T; Tsuboi, M; Lee, SH; He, J; Gao, SG; Chen, KN; Dooms, CA; Majem, M; Eigendorff, E; Martinengo, GL; Bylicki, O; Rodriguez-Abreu, D; Chaft, JE; Novello, S; Yang, J; Keller, SM; Samkari, A; Spicer, J

A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas

Lee, J; Park, S; Jung, HA; Lee, SH; Seo, S; Kim, SB; Kim, JW; Lee, KW; Kang, EJ; Kim, JW; Choi, YJ; Shim, BY; An, HJ; Park, LC; Shin, SH; Kim, JJ; Oh, SY; Kim, MK; Ahn, MJ

EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis

Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Cancer-Specific Sequences in the Diagnosis and Treatment of NUT Carcinoma

Lee, MS; An, S; Song, JY; Sung, M; Jung, K; Chang, ES; Choi, J; Oh, DY; Jeon, YK; Yang, H; Lakshmi, C; Park, S; Han, J; Lee, SH; Choi, YL

Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Ng, KW; Boumelha, J; Enfield, KSS; Almagro, J; Cha, HG; Pich, O; Karasaki, T; Moore, DA; Salgado, R; Sivakumar, M; Young, G; Molina-Arcas, M; Trecesson, SD; Anastasiou, P; Fendler, A; Au, LW; Shepherd, STC; Martinez-Ruiz, C; Puttick, C; Black, JRM; Watkins, TBK; Kim, H; Shim, S; Faulkner, N; Attig, J; Veeriah, S; Magno, N; Ward, S; Frankell, AM; Al Bakir, M; Lim, EL; Hill, MS; Wilson, GA; Cook, DE; Birkbak, NJ; Behrens, A; Yousaf, N; Popat, S; Hackshaw, A; TRACERx Consortium; CAPTURE Consortium; Hiley, CT; Litchfield, K; McGranahan, N; Jamal-Hanjani, M; Larkin, J; Lee, SH; Turajlic, S; Swanton, C; Downward, J; Kassiotis, G

Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells

Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW

Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance

Hwang, S; Hong, TH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Han, J; Ahn, YC; Pyo, H; Noh, JM; Lee, HY; Kim, HJ; Park, S; Ahn, MJ; Park, K; Lee, SH; Choi, YL; Kim, J

Lung adenocarcinoma promotion by air pollutants

Hill, W; Lim, EL; Weeden, CE; Lee, C; Augustine, M; Chen, K; Kuan, FC; Marongiu, F; Evans, EJ ; Moore, DA; Rodrigues, FS; Pich, O; Bakker, B; Cha, HG; Myers, R; van Maldegem, F; Boumelha, J; Veeriah, S; Rowan, A; Naceur-Lombardelli, C; Karasaki, T; Sivakumar, M; De, S; Caswell, DR; Nagano, A; Black, JRM; Martínez-Ruiz, C; Ryu, MH; Huff, RD; Li, S; Favé, MJ; Magness, A; Suárez-Bonnet, A; Priestnall, SL; Lüchtenborg, M; Lavelle, K; Pethick, J; Hardy, S; McRonald, FE; Lin, MH; Troccoli, CI; Ghosh, M; Miller, YE; Merrick, DT; Keith, RL; Al Bakir, M; Bailey, C; Hill, MS; Saal, LH; Chen, Y; George, AM; Abbosh, C; Kanu, N; Lee, SH; McGranahan, N; Berg, CD; Sasieni, P; Houlston, R; Turnbull, C; Lam, S; Awadalla, P; Grönroos, E; Downward, J; Jacks, T; Carlsten, C; Malanchi, I; Hackshaw, A; Litchfield, K; Lester, JF; DeGregori, J; Jamal-Hanjani, M; Swanton, C

Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020

Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment

Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY

A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)

Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI

Kim, HR; Jo, H; Kim, H; Hong, J; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ

Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors

Park, C; Jeong, DY; Choi, Y; Oh, YJ; Kim, J; Ryu, J; Paeng, K; Lee, SH; Ock, CY; Lee, HY

MHC II immunogenicity shapes the neoepitope landscape in human tumors

Kim, JY; Cha, HG; Kim, K; Sung, CH; An, JHY; Bang, H; Kim, H; Yang, JO; Chang, SH; Shin, I; Noh, SJ; Shin, I; Cho, DY; Lee, SH; Choi, JK

Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer

Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ

Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers

Kim, JE; Kim, H; Kim, B; Chung, HG; Chung, HH; Kim, KM; Kim, SH; Jeong, WK; Kim, YK; Min, JH; Heo, JS; Han, IW; Shin, SH; Park, HC; Yu, JI; Park, JO; Kim, ST; Hong, JY; Lee, SH; Lee, KH; Lee, JK; Lee, KT; Jang, KT; Park, JK

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma

Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH

High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities

Roh, W; Geffen, Y; Cha, H; Miller, M; Anand, S; Kim, J; Heiman, DI; Gainor, JF; Laird, PW; Cherniack, AD; Ock, CY; Lee, SH; Getz, G

Prognostic value of FOXP3+regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma

Hur, JY; Ku, BM; Park, S; Jung, HA; Lee, SH; Ahn, MJ

Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma

Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC br

Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K

Metabolic parameters on baseline F-18-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma

Kwon, HR; Cho, JH; Park, S; Lee, SH; Ahn, MJ; Choi, JY; Lee, KH; Jung, HA; Moon, SH

TCF1(+)PD-1(+) tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer

Koh, J; Kim, S; Woo, YD; Song, SG; Yim, J; Han, BGY; Lim, S; Ahn, HK; Mun, S; Kim, JS; Keam, B; Kim, YA; Lee, SH; Jeon, YK; Chung, DH

A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer

Kim, HR; Lee, SJ; Park, S; Jung, HA; Lee, SH; Jeong, HS; Chung, MK; Ahn, MJ

Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial

Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer

Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study

Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1

Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC

Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response

Choi, S; Cho, SI; Ma, M; Park, S; Pereira, S; Aum, BJ; Shin, S; Paeng, K; Yoo, D; Jung, W; Ock, CY; Lee, SH; Choi, YL; Chung, JH; Mok, TS; Kim, H; Kim, S

Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer

Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma

Kim, H; Heo, CM; Oh, J; Chung, HH; Lee, EM; Park, J; Lee, SH; Lee, KH; Lee, KT; Lee, JK; Cho, YK; Park, JK

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia

Cao, Y; Qin, S; Luo, S; Li, Z; Cheng, Y; Fan, Y; Sun, Y; Yin, X; Yuan, X; Li, W; Liu, T; Hsu, CH; Lin, X; Kim, SB; Kojima, T; Zhang, J; Lee, SH; Bai, Y; Muro, K; Doi, T; Bai, C; Gu, K; Pan, HM; Bai, L; Yang, JW; Cui, Y; Lu, W; Chen, J

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study

Park, S; Sun, JM; Choi, YL; Oh, D; Kim, HK; Lee, T; Chi, SA; Lee, SH; Choi, YS; Jung, SH; Ahn, MJ; Ahn, YC; Park, K; Shim, YM

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor

Ku, BM; Kim, YJ; Park, D; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Sun, JM

Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment

Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer

Ku, BM; Heo, JY; Kim, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Gene essentiality for tumour growth influences neoantigen-directed immunoediting

Bang, H; Park, JS; Kim, JY; Sung, C; An, J; Cho, DY; Lee, SH; Shim, SB; Choi, JK; Kim, K

Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma

Lee, YP; Jung, HA; Lee, MS; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Lee, JI; Lee, SH

Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach

Song, C; Park, H; Lee, HY; Lee, S; Ahn, JH; Lee, SH

Rarest of rare cases within the one thousand faces of atypical carcinoid: Pseudomesotheliomatous manifestation in a pregnant woman

Kim, H; Lee, HY; Lee, SH; Lee, IS; Choi, JY; Shim, YM

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience

Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies

Park, JG; Choi, BK; Lee, Y; Jang, EJ; Woo, SM; Lee, JH; Kim, KH; Hwang, H; Choi, W; Lee, SH; Yoo, BC

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment

Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH

Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system

Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma

Choi, Y; Aum, J; Lee, SH; Kim, HK; Kim, J; Shin, S; Jeong, JY; Ock, CY; Lee, HY

Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model

Koh, J; Kim, S; Lee, SN; Kim, SY; Kim, JE; Lee, KY; Kim, MS; Heo, JY; Park, YM; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Yang, S; Ha, SJ; Lim, YT; Ahn, MJ

Accurate Prognosis Prediction of Pancreatic Ductal Adenocarcinoma Using Integrated Clinico-Genomic Data of Endoscopic Ultrasound-Guided Fine Needle Biopsy

Park¹, JK; Kim, H; Son, DS; Kim, NKD; Sung, YK; Cho, M; Lee, C; Noh, DH; Lee, SH; Lee, KT; Lee, JK; Jang, KT; Park, WY; Lee, KH

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Lee¹, JS; Nair, NU; Dinstag, G; Chapman, L; Chung, YM; Wang, K; Sinha, S; Cha, H; Kim, D; Schperberg, AV; Srinivasan, A; Lazar, V; Rubin, E; Hwang, S; Berger, R; Beker, T; Ronai, ZE; Hannenhalli, S; Gilbert, MR; Kurzrock, R; Lee, SH; Aldape, K; Ruppin, E

High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program

Park¹, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

Lee¹, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Litchfield¹, K; Reading, JL; Puttick, C; Thakkar, K; Abbosh, C; Bentham, R; Watkins, TBK; Rosenthal, R; Biswas, D; Rowan, A; Lim, E; Al Bakir, M; Turati, V; Guerra-Assuncao, JA; Conde, L; Furness, AJS; Saini, SK; Hadrup, SR; Herrero, J; Lee, SH; Van Loo, P; Enver, T; Larkin, J; Hellmann, MD; Turajlic, S; Quezada, SA; McGranahan, N; Swanton, C

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors

Kim¹, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer

Ku¹, BM; Kim, Y; Lee, KY; Kim, SY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice

Lee¹, SH; Cho, SY; Yoon, YM; Park, CH; Sohn, JY; Jeong, JJ; Jeon, BN; Jang, M; An, C; Lee, S; Kim, YY; Kim, G; Kim, S; Kim, Y; Lee, GB; Lee, EJ; Kim, SG; Kim, HS; Kim, YM; Kim, H; Yang, HS; Kim, S; Kim, S; Chung, H; Moon, MH; Nam, MH; Kwon, JY; Won, S; Park, JS; Weinstock, GM; Lee, C; Yoon, KW; Park, H

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

Kojima¹, T; Shah, MIA; Muro, K; Francois, E; Adenis, A; Hsu, CH; Doi, T; Moriwaki, T; Kim, SB; Lee, SH; Bennouna, J; Kato, K; Shen, L; Enzinger, P; Qin, SK; Ferreira, P; Chen, J; Girotto, G; de la Fouchardiere, C; Senellart, H; Al-Rajabi, R; Lordick, F; Wang, RX; Suryawanshi, S; Bhagia, P; Kang, SP; Metges, JP

Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs

Kim¹, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

Treatment strategy for papillary renal cell carcinoma type 2 a case series of seven patients treated based on next generation sequencing data

Kim¹, JY; Jeong, HO; Heo, DS; Keam, B; Moon, KC; Kwak, C; Jang, J; Kim, S; Kim, JI; Lee, S; Lee, SH

Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

Koh¹, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy

Park¹, C; Jeong, K; Park, JH; Jung, S; Bae, JM; Kim, K; Ock, CY; Kim, M; Keam, B; Kim, TM; Jeon, YK; Lee, SH; Lee, JS; Kim, DW; Kang, GH; Chung, DH; Heo, DS

Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status

Lee¹, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Park¹, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ

Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Hong¹, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations?

Jung¹, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

Jung¹, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Park¹, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy

Park¹, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K

Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer

Jung¹, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K

Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma

Kim¹, HK; Joung, JG; Choi, YL; Lee, SH; Park, BJ; Choi, YS; Ryu, D; Nam, JY; Lee, MS; Park, WY; Hwang, S; Cha, H; Kim, HS; Lee, S; Jung, Y; Lee, JE; Doh, J; Paik, S; Kang, JH; Lee, J; Kim, J

Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)

Jung¹, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K

Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations

Kim¹, G; Kim, J; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Park, YJ; Choi, JY; Lee, KH; Lee, SH; Moon, SH

PDX models of human lung squamous cell carcinoma consideration of factors in preclinical and co-clinical applications

Jung¹, HY; Kim, TH; Lee, JE; Kim, HK; Cho, JH; Choi, YS; Shin, S; Lee, SH; Rhee, H; Lee, HK; Choi, HJ; Jang, HY; Lee, S; Kang, JH; Choi, YA; Lee, S; Lee, J; Choi, YL; Kim, J

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer real-world data in Korea

Kim¹, H; Kwon, M; Kim, B; Jung, HA; Sun, JM; Lee, SH; Park, K; Ahn, MJ

HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients

Shim¹, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH

Evaluating entrectinib as a treatment option for non-small cell lung cancer

Lee¹, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?

Lee¹, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma

Lee¹, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer

Lee¹, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

Kim¹, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO

Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests

Byeon¹, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping

Hur¹, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

New Approaches to SCLC Therapy: From the Laboratory to the Clinic

Poirier¹, JT; George, J; Owonikoko, TK; Berns, A; Brambilla, E; Byers, LA; Carbone, D; Chen, HJ; Christensen, CL; Dive, C; Farago, AF; Govindan, R; Hann, C; Hellmann, MD; Horn, L; Johnson, JE; Ju, YS; Kang, SM; Krasnow, M; Lee, J; Lee, SH; Lehman, J; Lok, B; Lovly, C; MacPherson, D; McFadden, D; Minna, J; Oser, M; Park, K; Park, KS; Pommier, Y; Quaranta, V; Ready, N; Sage, J; Scagliotti, G; Sos, ML; Sutherland, KD; Travis, WD; Vakoc, CR; Wait, SJ; Wistuba, I; Wong, KK; Zhang, H; Daigneault, J; Wiens, J; Rudin, CM; Oliver, TG

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

Ku¹, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Junction Location Identifier (JuLI) Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology

Shin¹, HT; Kim, NKD; Yun, JW; Lee, B; Kyung, S; Lee, KW; Ryu, D; Kim, J; Bae, JS; Park, D; Choi, YL; Lee, SH; Ahn, MJ; Park, K; Park, WY

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Cho¹, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence

Byeon¹, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Development of tuberculosis in cancer patients receiving immune checkpoint inhibitors

Im¹, Y; Lee, J; Kim, SJ; Koh, WJ; Jhun, BW; Lee, SH

Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

Shin¹, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

Kim¹, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea

Lee¹, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ

In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing

Park¹, S; Lee, SH; Park, K

Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease

Shin¹, SH; Park, HY; Im, Y; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, HY; Lee, SH

Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing

Kim¹, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Kim¹, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

Park¹, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Jung¹, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

Cho¹, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma

Park¹, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

NPM1 as a potential therapeutic target for atypical teratoid/rhabdoid tumors

Phi¹, JH; Sun, CH; Lee, SH; Lee, S; Park, I; Choi, SA; Park, SH; Lee, JY; Wang, KC; Kim, SK; Yun, H; Park, CK

A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Keam¹, B; Lee, KW; Lee, SH; Kim, JS; Kim, JH; Wu, HG; Eom, KY; Kim, S; Ahn, SH; Chung, EJ; Kwon, SK; Jeong, WJ; Jung, YH; Kim, JW; Heo, DS

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

Zhou¹, CC; Kim, SW; Reungwetwattana, T; Zhou, JY; Zhang, YP; He, JX; Yang, JJ; Cheng, Y; Lee, SH; Bu, LL; Xu, TT; Yang, L; Wang, C; Liu, T; Morcos, PN; Lu, Y; Zhang, L

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

Park¹, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma

Cho¹, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor

Lee¹, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ

Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery

Cho¹, WK; Oh, D; Kim, HK; Ahn, YC; Noh, JM; Shim, YM; Zo, JI; Choi, YS; Sun, JM; Lee, SH; Ahn, MJ; Park, K; Nam, H

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

Kim¹, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kim¹, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer

Lee¹, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13

Yoo¹, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Park¹, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon¹, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Kim¹, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K

Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer

Moon¹, SH; Kim, J; Joung, JG; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Choi, JY; Lee, KH; Kim, BT; Lee, SH

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer

Lee¹, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ

Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients

Lee¹, SH; Lee, B; Shim, JH; Lee, KW; Md, JWY; Kim, SY; Kim, TY; Kim, YH; Ko, YH; Chung, HC; Yu, CS; Lee, J; Rha, SY; Kim, TW; Jung, KH; Im, SA; Moon, HG; Cho, S; Kang, JH; Kim, J; Kim, SK; Ryu, HS; Ha, SY; Il Kim, J; Chung, YJ; Kim, C; Kim, HL; Park, WY; Noh, DY; Park, K

Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion

Kim¹, H; Oh, D; Ahn, YC; Park, K; Ahn, MJ; Lee, SH; Sun, JM; Shim, YM; Zo, JI; Choi, YS; Kim, HK; Cho, JH

A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Noneclear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus

Park¹, I; Lee, SH; Lee, JL

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial

Lim¹, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice

Park¹, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ

Integrin beta 3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC

Noh¹, KW; Sohn, I; Song, JY; Shin, HT; Kim, YJ; Jung, K; Sung, M; Kim, M; An, S; Han, J; Lee, SH; Lee, MS; Choi, YL

Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma

Lee¹, J; Jung, HA; Kim, Y; Choi, S; Han, J; Choi, YL; Lee, SH; Ahn, JS; Park, K; Sun, JM

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

Lee¹, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ

The more and the heavier may not always be an answer

Pyo¹, H; Lee, SH; Kim, J

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

Ku¹, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy

Park¹, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer

Cho¹, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma

Cho¹, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)

Sun¹, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor

Park¹, S; Ha, S; Lee, SH; Paeng, JC; Keam, B; Kim, TM; Kim, DW; Heo, DS

Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer

Park¹, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Kim¹, HI; Kim, M; Lee, SH; Park, SY; Kim, YN; Kim, H; Jeon, MJ; Kim, TY; Kim, SW; Kim, WB; Kim, SW; Lee, DH; Park, K; Ahn, MJ; Chung, JH; Shong, YK; Kim, WG; Kim, TH

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer

Sun¹, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K

Prevalence and detection of low-allele-fraction variants in clinical cancer samples

Shin¹, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY

Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer

Noh¹, KW; Lee, MS; Lee, SE; Song, JY; Shin, HT; Kim, YJ; Oh, DY; Jung, K; Sung, M; Kim, M; An, S; Han, J; Shim, YM; Zo, JI; Kim, J; Park, WY; Lee, SH; Choi, YL

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer

Lee¹, MY; Ku, BM; Kim, HS; Lee, JY; Lim, SH; Sun, JM; Lee, SH; Park, K; Oh, YL; Hong, M; Jeong, HS; Son, YI; Baek, CH; Ahn, MJ

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer

Ku¹, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors

Kim¹, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

Lee¹, JK; Lee, J; Kim, S; Kim, S; Youk, J; Park, S; An, Y; Keam, B; Kim, DW; Heo, DS; Kim, YT; Kim, JS; Kim, SH; Lee, JS; Lee, SH; Park, K; Ku, JL; Jeon, YK; Chung, DH; Park, PJ; Kim, J; Kim, TM; Ju, YS

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer

Ku¹, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ

Glutaminase 2 expression is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma

Kim¹, S; Kim, JE; Kim, YH; Hwang, T; Kim, SK; Xu, WJ; Shin, JY; Kim, JI; Choi, H; Kim, HC; Cho, HR; Choi, A; Chowdhury, T; Seo, Y; Dho, YS; Kim, JW; Kim, DG; Park, SH; Kim, H; Choi, SH; Park, S; Lee, SH; Park, CK

Comprehensive somatic genome alterations of urachal carcinoma

Lee¹, S; Lee, J; Sim, SH; Lee, Y; Moon, KC; Lee, C; Park, WY; Kim, NKD; Lee, SH; Lee, H

Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma

Lee Y1¹, Park S2, Lee SH3,4, Lee H5.

EGFR TKI combination with immunotherapy in non-small cell lung cancer

Ahn MJ1¹, Sun JM1, Lee SH1, Ahn JS1, Park K1.

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

Kim ST1¹, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.

Osimertinib for the treatment of non-small cell lung cancer

Sun JM1¹, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.

A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer

Lee JY¹, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

Lee SH1¹, Lee JK2, Ahn MJ1, Kim DW2, Sun JM1, Keam B2, Kim TM2, Heo DS2, Ahn JS1, Choi YL3, Min HS4, Jeon YK4, Park K1.

Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC

Lee SH1¹, Lee JK2.

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors

Lim SH1¹, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma

Cha Y1¹, Kim YJ2, Lee SH1,3, Kim TM1, Choi SH4, Kim DW1, Park CK5, Kim IH6, Kim JH2, Kim E7, Choi B7, Kim CY8, Kim IA9, Heo DS1.

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea

Kim BS1¹, Seol HJ2, Nam DH2, Park CK3, Kim IH4, Kim TM5, Kim JH6, Cho YH6, Yoon SM7, Chang JH8, Kang SG8, Kim EH8, Suh CO9, Jung TY10, Lee KH11, Kim CY12, Kim IA13, Hong CK14, Yoo H15, Kim JH16, Kang SH17, Kang MK18, Kim EY19, Kim SH20, Chung DS21, Hwang SC22, Song JH23, Cho SJ24, Lee SI25, Lee YS26, Ahn KJ27, Kim SH28, Lim DH29, Gwak HS30, Lee SH31, Hong YK32.

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision

Ahn MJ1¹, Sun JM2, Lee SH2, Ahn JS2, Park K2.

Prognostic significance of clinical and F-18-FDG PET/CT parameters for post-distant metastasis survival in head and neck squamous cell carcinoma patients

Cho JK¹, Hyun SH, Choi JY, Choi N, Kim MJ, Lee SH, Baek KH, Jeong HS

Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study

Lim SH1¹, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.

AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells

Ku BM1¹, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

Byeon S1¹, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria

Kim HS1¹, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Lee JY1¹, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers

Lee B1¹,2, Lee T1, Lee SH3,2, Choi YL1,2, Han J1.

Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma

Kim HS1¹, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

Ku BM1¹, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.

Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer

Park S1¹, Park S1, Lee SH1,2, Suh B3, Ock CY1, Keam B1, Kim TM1, Kim DW1, Kim YW1, Heo DS1.

Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma

Lee DY1¹, Won JK2, Lee SH3, Park do J4, Jung KC2, Sung MW5, Wu HG6, Kim KH5, Park YJ4, Hah JH5.

Pembrolizumab for the treatment of non-small cell lung cancer

Lim SH¹, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)

Lee JY1¹, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.

Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis

Cha S1¹, Lee J2, Shin JY3, Kim JY4, Sim SH5, Keam B6,7, Kim TM8,9, Kim DW10,11, Heo DS12,13, Lee SH14,15,16,17, Kim JI18,19,20,21.

Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)

Lee JY1¹, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.

Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas

Park CK1¹, Park I2, Lee S3, Sun CH3, Koh Y4, Park SH5, Kim JE1, Yun H3, Lee SH6.

The MISSION Impossible No, the Journey Should Continue with Better Targeting!

Lee SH1¹, Park K.

A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors

Kim HS1¹, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.

Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs

Lee SJ1¹, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.

Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas

Kim BS1¹, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, Lee JI, Park CK, Kong DS.

Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas

Kim JE1¹, Cho HR2, Xu WJ3, Kim JY1, Kim SK4, Kim SK1,5, Park SH6, Kim H2, Lee SH7, Choi SH2, Park S3, Park CK1.

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy

Kim M1¹, Ku JH2, Kwak C2, Kim HH2, Lee E2, Keam B3, Kim TM3, Heo DS3, Lee SH4, Moon KC5.

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

Park SH1¹, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.

Arsenic trioxide represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60

Han SS1¹, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S.

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission

Lee SH1¹, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.

Activation of Rafl and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells

Park S1¹, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Lee JH.

Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia

Park J1¹, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.